Holen Sie sich die Stockscreener-App
46.65
4.07%
-1.98
Handel nachbörslich:
46.70
0.05
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$48.63
Offen:
$48.27
24-Stunden-Volumen:
19.73M
Relative Volume:
1.35
Marktkapitalisierung:
$94.95B
Einnahmen:
$48.03B
Nettoeinkommen (Verlust:
$6.05B
KGV:
15.75
EPS:
2.9615
Netto-Cashflow:
$15.30B
1W Leistung:
-0.09%
1M Leistung:
+6.51%
6M Leistung:
+5.73%
1J Leistung:
-20.26%
1-Tages-Spanne:
$46.12
$48.37
1-Wochen-Bereich:
$46.12
$49.99
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.65 | 99.00B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Is Bristol Myers Squibb Company stock a safe investment in uncertain markets2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
Good Life Advisors LLC Decreases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company (BRM) stock a contrarian opportunityMarket Trend Review & Safe Capital Preservation Plans - newser.com
Boston Partners Sells 3,760,655 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target - Finviz
Is Bristol Myers Squibb Company Celegne Contingent stock resilient in recession scenarios2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Police & Firemen s Retirement System of New Jersey Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Purchases 15,599 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Arvest Bank Trust Division - MarketBeat
Allianz SE Lowers Position in Bristol Myers Squibb Company $BMY - MarketBeat
Blood thinner failure thins BMS shares - The Pharma Letter
Bristol Myers, J&J halt heart drug trial after interim review - ETPharma.com
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? - Benzinga
Scotiabank Initiates Coverage on Bristol Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers, J&J’s new blood thinner fails first big test - BioPharma Dive
Bristol Myers, J&J stop blood clotting drug trial after interim review - Reuters
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy - Benzinga
Wealth Alliance LLC Cuts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Vestmark Advisory Solutions Inc. Trims Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb shares slide after halting key heart trial - MSN
Bristol-Myers Squibb stock falls after discontinuing acute coronary trial By Investing.com - Investing.com Canada
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com
Bristol Myers (BMY) Drops Following Phase 3 Trial Halt - GuruFocus
Bristol Myers falls after halting heart drug trial - TradingView
Bristol Myers Squibb discontinues Librexia ACS trial after review By Investing.com - Investing.com Canada
Bristol Myers Squibb Company $BMY Shares Sold by Nwam LLC - MarketBeat
Cherokee Insurance Co Takes $1.42 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Update on phase 3 Librexia ACS trial - MarketScreener
Candriam S.C.A. Sells 92,461 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Forsta AP Fonden Has $19.34 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Q&A: BioNTech co-founders discuss bispecific efforts, Bristol Myers deal, and the irony of competing with Pfizer - Endpoints News
Wealth Quarterback LLC Raises Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by KBC Group NV - MarketBeat
ProShare Advisors LLC Acquires 37,125 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb’s Oncology Strategy Gains Momentum - AD HOC NEWS
SCRI, BMS Expand Collaboration to Accelerate Patient Enrollment - Contract Pharma
Bristol Myers Squibb, Sarah Cannon expand oncology trial partnership - Investing.com
Does Bristol-Myers Squibb’s Rebound Signal Opportunity After Recent Biotech Acquisitions? - Yahoo Finance
Bristol Myers (NYSE: BMY) and SCRI broaden cancer trial access via Accelero at 200+ sites - Stock Titan
Zions Bancorporation National Association UT Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Evotec and BMS partnership yields IND approval - BioWorld MedTech
Evotec Receives $5 Million Milestone Payment From Bristol Myers Under Protein Degradation Partnership - MarketScreener
Bristol Myers Squibb Company $BMY Stake Boosted by denkapparat Operations GmbH - MarketBeat
Privacy notice center - Bristol Myers Squibb
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - ACCESS Newswire
Published on: 2025-11-12 00:59:26 - newser.com
Evotec gets USD 5 mln milestone payment from Bristol Myers Squibb - MarketScreener
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership - TradingView
Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating - Insider Monkey
Jim Cramer on Bristol-Myers: “I’m Backing off on It” - Insider Monkey
Bristol Myers Squibb Co. Stock Rises Monday, Still Underperforms Market - 富途牛牛
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):